SPY326.52+2.56 0.79%
DIA264.35+1.07 0.41%
IXIC10,745.28+157.46 1.49%
News
ORIC
--
0.00%
--
The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29)
Benzinga · 4d ago
The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14)
Benzinga · 07/15 11:30
The Daily Biotech Pulse: Blueprint, Roche Ink $1.7B Cancer Drug Collaboration, INmune's Positive Alzheimer's Readout, Edwards, Abbott Settle Patent Lawsuits
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 13)
Benzinga · 07/14 12:04
The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 9) Affimed NV (NASDAQ: AFMD)
Benzinga · 07/10 11:25
The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8)
Benzinga · 07/09 12:09
The Daily Biotech Pulse: Chiasma, Heron Await FDA Decisions, DBV Restructures, 3 Biopharmas Make Wall Street Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 25)
Benzinga · 06/26 12:28
ORIC Pharmaceuticals Presents Preclinical Data on Glucocorticoid Receptor Antagonist and CD73 Inhibitor Programs at the 2020 American Association for Cancer Research Virtual Annual Meeting II
GlobeNewswire · 06/22 14:00
ORIC Pharmaceuticals Presents Preclinical Data On Glucocorticoid Receptor Antagonist And CD73 Inhibitor Programs At The 2020 American Association For Cancer Research Virtual Annual Meeting II
SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic
Benzinga · 06/22 13:06
ORIC Pharmaceuticals Appoints Lori Kunkel, M.D., to its Board of Directors
GlobeNewswire · 06/09 21:15
The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech Stocks Hitting 52-week Highs June 3)
Benzinga · 06/04 12:13
ORIC Pharmaceuticals Announces Five Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting II
GlobeNewswire · 05/27 11:30
ORIC Pharmaceuticals to Present at the Jefferies 2020 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 26, 2020 -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address.
GlobeNewswire · 05/26 10:30
ORIC Pharmaceuticals EPS misses by $3.96
ORIC Pharmaceuticals (NASDAQ:ORIC): Q1 GAAP EPS of -$4.46 misses by $3.96. Cash and equivalents of $79.44M (-10.9% Q/Q) Press Release
seekingalpha · 05/21 01:20
ORIC Pharmaceuticals Reports First Quarter 2020 Financial and Operational Results
GlobeNewswire · 05/20 21:15
ORIC Pharmaceuticals Q1 Sales $307.000K Down From $331.000K YoY
ORIC Pharmaceuticals (NASDAQ:ORIC) reported $307.000 thousand in sales this quarter. This is a 7.25 percent decrease over sales of $331.000 thousand the same period last year.
Benzinga · 05/20 20:18
Guggenheim Initiates Coverage On ORIC Pharmaceuticals with Buy Rating, Announces Price Target of $45
Guggenheim initiates coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy rating and announces Price Target of $45.
Benzinga · 05/19 11:43
Jefferies Initiates Coverage On ORIC Pharmaceuticals with Buy Rating, Announces Price Target of $40
Jefferies initiates coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy rating and announces Price Target of $40.
Benzinga · 05/19 11:42
Citigroup Initiates Coverage On ORIC Pharmaceuticals with Neutral Rating, Announces Price Target of $35
Citigroup initiates coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with a Neutral rating and announces Price Target of $35.
Benzinga · 05/19 11:40
Oric Pharmaceuticals started at overweight with $40 stock price target at J.P. Morgan
marketwatch.com · 05/19 07:38
The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Earnings Flow Slows
Biotech stocks had another up week, with the American Society of Gene & Stem Cell Therapy virtual conference presentations and the ASCO abstracts made available online Thursday calling the shots. Earnings news flow continued to taper.
Benzinga · 05/17 16:30